The Journal of the Pharmacy Society of Wisconsin
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact

Molnupiravir: Review of a New Oral Antiviral Agent Approved for Emergency Use Authorization in the United States for Coronavirus Disease 2019

by Vanessa Lei, PharmD Candidate 2023, Payeng Lor, PharmD Candidate 2023, Vanessa Sanchez, PharmD Candidate 2023, Kong Choua Thao, PharmD Candidate 2023, Zachary Hovis, PharmD, BCACP 

"Coronavirus disease 2019 (COVID-19) is a severe acute respiratory illness caused by the novel coronavirus SARS-CoV-2 and resulting in an ongoing global pandemic. As of January 2022, SARS CoV-2 totaled 64,720,612 cases and 843,718 deaths in the U.S. alone.1 While all populations are at risk of contracting COVID-19, people who are older, are immunocompromised, or who have certain comorbidities (e.g. cardiovascular disease, diabetes, or chronic lung disease) have a much higher risk of progressing to severe disease and hospitalization.2 Due to the high transmissibility and infectious nature of COVID-19, many preventive measures, such as the use of masks in public settings and social distancing, have been put into place nationally. These preventive measures play an essential role
in combating widespread transmission of the novel coronavirus." 



Keywords: United States, COVID-19 Vaccines, Ritonavir, COVID-19, Hydroxychloroquine, SARS-CoV-2, Remdesivir, Molnupiravir, Cardiovascular Diseases, Outpatients, Pandemics, Physical Distancing, United States Food and Drug Administration, Vaccination, Antiviral Agents, Cost of Illness, Hospitalization, Disease Progression, mRNA Vaccines, Intubation Intratracheal, Delivery of Health Care, Diabetes Mellitus

​Download PDF

2022 July/August Table of Contents 

The Journal of the Pharmacy Society of Wisconsin


Past Issues

2020
2021
​2022
2019
2018
2017

About PSW

www.pswi.org

Contact Us

thejournal@pswi.org
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact